Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 5/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566055 | 0.93 | C3AR1 (0.45) | C3AR1PDPK1 | |
| SCHEMBL4991622 | 0.93 | C3AR1 (0.45) | C3AR1PDPK1 | |
| SCHEMBL14091191 | 0.90 | C3AR1 (0.42) | C3AR1FOLH1SHMT1PDPK1TGM2 | |
| SCHEMBL4989792 | 0.90 | C3AR1 (0.40) | C3AR1FOLH1PDPK1TGM2ALB | |
| SCHEMBL4986840 | 0.90 | C3AR1 (0.42) | C3AR1FOLH1SHMT1PDPK1TGM2 | |
| SCHEMBL4990654 | 0.90 | C3AR1 (0.45) | C3AR1FOLH1PDPK1TGM2 | |
| SCHEMBL4425979 | 0.87 | PADI1 (0.40) | C3AR1PDPK1 | |
| SCHEMBL4992633 | 0.87 | C3AR1 (0.42) | C3AR1FOLH1PDPK1 | |
| SCHEMBL4986550 | 0.86 | C3AR1 (0.41) | C3AR1PDPK1 | |
| SCHEMBL4995283 | 0.86 | C3AR1 (0.42) | C3AR1FOLH1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | C3AR1 1/4885FOLH1 2725/4885SHMT1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.